Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

4(80.0%)

Phase 2

1(20.0%)

5Total

Phase 3(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07450664Enrolling By Invitation

Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

Role: lead

NCT05701774Phase 3Active Not Recruiting

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

Role: lead

NCT04102839Completed

PWS Outcomes Assessment Study

Role: lead

NCT03714373Phase 3Completed

Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

Role: lead

NCT03440814Phase 3Completed

A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

Role: lead

NCT05532020Phase 2Unknown

An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

Role: lead

NCT04086810Phase 3Withdrawn

An Open-Label Study of DCCR Tablet in Patients With PWS

Role: lead

All 7 trials loaded